9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
Open accessThe DOI matches its Crossref record; 82 of the 84 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc20-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc20-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given the demonstrated benefits of SGLT2 inhibitors, the updated American Diabetes Association guidelines10 and the American College of Cardiology expert consensus statement11 now recommend their use for diabetic patients who have or are at high risk for cardiovascular disease, CKD, or heart failure regardless of current glycemic control.”
From Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US (2021) · cites this paper as [10]
In the citing paper
“All recommend SGLT2 inhibition for patients with T2DM and eGFR as low as 30 mL/min/1.73 m2, particularly if severely increased albuminuria is present.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [85]
In the citing paper
“Major national and international organizations are rapidly updating recommendations and guidelines (Table 4) (85–88).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [85]
In the citing paper
“In the US, the 2020 national median drug acquisition cost of GLP-1RAs ranges from $634 per month to $835 per month,27·41 although the out-of-pocket cost borne by patients varies considerably by insurance formulary and coverage.”
From Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review (2020) · cites this paper as [27]
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“may reduce risk of cardiovascular events and death (35).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M. B., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 965
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682 · cited 1×
“first-line therapy hasbeneficial effects on A1C, weight, and cardiovascular mortality (36); there is little systematic data”
BackgroundThreshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“with type 1 diabetes (15,16), and recent evidence suggests that a closed-loop system is superior to sensor-augmented pump therapy for glycemic control and reduction of hypoglycemia over 3 months of comparison in children and adults with type 1 diabetes (17).”
BackgroundHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609
Research works printed but not linked: 1
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
Cited by
Items 201–300 of 958
Sayeli, V. K., & Shenoy, A. K. (2021) · Journal of Ayurveda and Integrative Medicine · doi:10.1016/j.jaim.2021.04.010 · Cited by 34
“org/licenses/by Maintaining blood glucose in normal range and preventing complications due to long-term hyperglycaemia are the important goals of therapy in management of DM [4].”
BackgroundRea, F., Ciardullo, S., Savaré, L., Perseghin, G., & Corrao, G. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109035 · Cited by 33
Effects of diet and antihyperglycemic drugs on erectile dysfunction: A systematic review
Defeudis, G., Mazzilli, R., Tommaso, A. M. D., Zamponi, V., Carlomagno, F., Tuccinardi, D., Watanabe, M., Faggiano, A., & Gianfrilli, D. (2022) · Andrology · doi:10.1111/andr.13192 · Cited by 35
Chronic kidney disease detection, staging and treatment in cardiovascular disease prevention
Lamprea-Montealegre, J. A., Shlipak, M. G., & Estrella, M. M. (2021) · Heart · doi:10.1136/heartjnl-2020-318004 · Cited by 36
Williams, D. M., Ruslan, A. M., Khan, R., Vijayasingam, D., Iqbal, F., Shaikh, A., Lim, J., Chudleigh, R., Peter, R., Udiawar, M., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01015-z · Cited by 31
Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study
Ueda, P., Wintzell, V., Melbye, M., Eliasson, B., Svensson, A.-M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., Svanström, H., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05508-1 · Cited by 31
Saunders, I. M., Tan, M., Koura, D. T., & Young, R. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2443 · Cited by 32
Li, Y., Sung, P., Yang, Y., Chiang, J. Y., Yip, H., & Yang, C. (2021) · Communications Biology · doi:10.1038/s42003-021-01652-x · Cited by 31
Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial
Riddle, M. C., Gerstein, H. C., Xavier, D., Cushman, W. C., Leiter, L. A., Raubenheimer, P. J., Atisso, C. M., Raha, S., Varnado, O. J., Кониг, М., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab065 · Cited by 31
Metformin Attenuates Postinfarction Myocardial Fibrosis and Inflammation in Mice
Loi, H., Крамар, С., Laborde, C., Marsal, D. J., Pizzinat, N., Cussac, D., Roncalli, J. G., Boal, F., Tronchère, H., Oleshchuk, O., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179393 · Cited by 31
Dihoum, A., Rena, G., Pearson, E. R., Lang, C. C., & Mordi, I. R. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2196010 · Cited by 33
Tang, L.-Y., Xiao, M., Cai, S., Mou, H., & Li, D. (2023) · Foods · doi:10.3390/foods12132600 · Cited by 34
Bruemmer, D., & Nissen, S. E. (2020) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000199 · Cited by 34
Chiang, C., Ueng, K.-C., Chao, T., Lin, T., Wu, Y.-J., Wang, K.-L., Sung, S., Yeh, H., Li, Y., Liu, P., et al. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000359 · Cited by 31
“43 Considering safety, efficacy, and onset of benefit, most of guidelines recommended metformin as the first-line antidiabetic drug for primary prevention, 46 despite of different opinions.”
InfluentialChan, J. C. N., Paldánius, P. M., Mathieu, C., Stumvoll, M., Matthews, D. R., & Del Prato, S. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14192 · Cited by 24
Diabetic neuropathy in children and youth: New and emerging risk factors
Akıncı, G., Savelieff, M. G., Gallagher, G., Callaghan, B. C., & Feldman, E. L. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13153 · Cited by 33
Berndt, J., Ooi, S. L., & Pak, S. C. (2021) · Molecules · doi:10.3390/molecules26164822 · Cited by 33
Vlacho, B., Simarro, F. L., Mata‐Cases, M., Miravet-Jiménez, S., Escribano‐Serrano, J., Asensio, D., Cortés, X., & Franch‐Nadal, J. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.10.004 · Cited by 30
Yoon, W., Chang, J. H., Kim, J. H., Kim, Y. J., Jung, T., Yoo, H., Kim, S.-H., Ko, Y.-C., Nam, D., Kim, T. M., et al. (2023) · Discover Oncology · doi:10.1007/s12672-023-00678-3 · Cited by 30
Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists
Kane, M. P., Triplitt, C. L., & Solis‐Herrera, C. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa413 · Cited by 41
Escobar, C., Barrios, V., Cosín, J., Martínez, J. M. G., Rodrigo, A. I. H., Cortés, C. O., Llergo, J. T., Requeijo, C., Solà, I., & Martínez‐Zapata, M. J. (2021) · Diabetic Medicine · doi:10.1111/dme.14502 · Cited by 31
Experience of living with type 1 diabetes in a low-income country: a qualitative study from Liberia
Adler, A. J., Trujillo, C., Schwartz, L. N., Drown, L., Pierre, J., Noble, C., Allison, T., Cook, R. L., Randolph, C., & Bukhman, G. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-049738 · Cited by 32
An update on microneedle-based systems for diabetes
Li, W. X., Zhang, X. P., Chen, B. Z., Fei, W. M., Cui, Y., Zhang, C. Y., & Guo, X. D. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01113-2 · Cited by 30
Defeudis, G., Tommaso, A. M. D., Rosa, C. D., Cimadomo, D., Khazrai, Y. M., Faggiano, A., Cincione, R. I., Napoli, N., & Mazzilli, R. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123382 · Cited by 35
Insulin Injection Practices in a Population of Canadians with Diabetes: An Observational Study
Bari, B., Corbeil, M.-A., Farooqui, H. S., Menzies, S., Pflug, B. K., Smith, B. K., Vasquez, A. R., & Berard, L. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00913-y · Cited by 30
Chang, K.-C., Shao, S.-C., Kuo, S., Yang, C.-Y., Chen, H.-Y., Chan, Y.-Y., & Ou, H.-T. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01148-8 · Cited by 28
Insulin strategies for dietary fat and protein in type 1 diabetes: A systematic review
Smith, T. A., Marlow, A. L., King, B. R., & Smart, C. E. (2021) · Diabetic Medicine · doi:10.1111/dme.14641 · Cited by 30
Hwang, J. G., Lee, S., Huh, W., Han, J., Oh, J., Jang, I., & Yu, K. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15348 · Cited by 29
Qu, C., Tan, X., Hu, Q., Tang, J., Wang, Y., He, C., He, Z., Li, B., Fu, X., & Du, Q. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26863 · Cited by 32
“Similar to AS-IV, metformin, the main drug used to treat T2DM [126], increases AMP-activated protein kinase activity and phosphorylation to control blood glucose levels [127].”
BackgroundAndersen, G., Meiffren, G., Famulla, S., Heise, T., Ranson, A., Seroussi, C., Eloy, R., Gaudier, M., Charvet, R., Chan, Y., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14302 · Cited by 29
Bensignor, M. O., Bomberg, E. M., Bramante, C. T., Divyalasya, T. V. S., Hale, P. M., Ramesh, C. K., Rudser, K. D., & Kelly, A. S. (2021) · Pediatric Obesity · doi:10.1111/ijpo.12778 · Cited by 34
Lee, T.-W., Lee, T.-I., Lin, Y.-K., Chen, Y.-C., Kao, Y.-H., & Chen, Y.-J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03648-y · Cited by 27
Type 2 diabetes mellitus management in patients with chronic kidney disease: an update
Kleinaki, Z., Kapnisi, S., Theodorelou‐Charitou, S., Nikas, I. P., & Paschou, S. Α. (2020) · HORMONES · doi:10.1007/s42000-020-00212-y · Cited by 32
Boye, K. S., Mody, R., Lage, M. J., Douglas, S. D., & Patel, H. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00838-6 · Cited by 30
Roy, A., Maiti, A., Sinha, A., Baidya, A., Basu, A. K., Sarkar, D., Sanyal, D., Biswas, D., Maisnam, I., Pandit, K., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00921-y · Cited by 27
Expert Consensus on Telemedicine Management of Diabetes (2020 Edition)
Zhang, B. (2021) · International Journal of Endocrinology · doi:10.1155/2021/6643491 · Cited by 28
“Metformin: this drug has an excellent antihyperglycemic effect, and it has no risk of hypoglycemia when used as a monotherapy [8, 15].”
BackgroundUneda, K., Kawai, Y., Yamada, T., Kinguchi, S., Azushima, K., Kanaoka, T., Toya, Y., Wakui, H., & Tamura, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-89620-7 · Cited by 28
Wei, S., Brejnrod, A., Trivedi, U., Mortensen, M. S., Johansen, M. Y., Karstoft, K., Vaag, A. A., Ried‐Larsen, M., & Sørensen, S. J. (2021) · Gut Microbes · doi:10.1080/19490976.2021.2005407 · Cited by 31
Consoli, A., Czupryniak, L., Duarte, R., Jermendy, G., Kautzky‐Willer, A., Mathieu, C., Melo, M., Mosenzon, O., Nobels, F. R. E., Παπάνας, Ν., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14102 · Cited by 26
Švehlíková, E., Mursic, I., Augustin, T., Magnes, C., GERRING, D. J., Jezek, J., Schwarzenbacher, D., Ratzer, M., Wolf, M., Howell, S. J., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1017 · Cited by 29
Bonora, B. M., Rigato, M., Frison, V., D'Ambrosio, M., Tadiotto, F., Lapolla, A., Simioni, N., Paccagnella, A., Avogaro, A., & Fadini, G. P. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108686 · Cited by 26
Cardiovascular Risk/Disease in Type 2 Diabetes Mellitus
Román, G., & Stoian, A. P. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97422 · Cited by 30
Al‐Saleh, Y., Sabico, S., Al-Furqani, A., Jayyousi, A., Alromaihi, D., Ba-Essa, E. M., Alawadi, F., Alkaabi, J., Hassanein, M. M., Alsifri, S. N., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01059-1 · Cited by 37
Real, J., Vlacho, B., Ortega, E., Vallés, J. A., Mata‐Cases, M., Castelblanco, E., Wittbrodt, E. T., Fenici, P., Kosiborod, M., Mauricio, D., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01323-5 · Cited by 29
Role of Intermittent Fasting in the Management of Prediabetes and Type 2 Diabetes Mellitus
Ojo, T. K., Joshua, O. O., Ogedegbe, O. J., Oluwole, O., Ayoade, A. O., & Jesuyajolu, D. A. (2022) · Cureus · doi:10.7759/cureus.28800 · Cited by 31
Mittman, B. G., Le, P. N. B., Payne, J. Y., Ayers, G. T., & Rothberg, M. B. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2303413 · Cited by 26
“…American Diabetes Association (ADA) guidelines for standards of care for people with T2D strengthened recommendations for these drugs as first-line treatments for people with T2D with comorbid renal or cardiovascular disease, due to growing evidence of their benefits beyond glycemic control 29 .”
BackgroundOptimizing Therapeutic Outcomes With Oral Semaglutide: A Patient-Centered Approach
Isaacs, D. M., Kruger, D. F., & Spollett, G. R. (2020) · Diabetes Spectrum · doi:10.2337/ds20-0016 · Cited by 26
Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
Brunton, S., Mosenzon, O., & Wright, E. E. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798162 · Cited by 29
Remogliflozin: the new low cost SGLT-2 inhibitor for type 2 diabetes mellitus
Atal, S., Fatima, Z., Singh, S., Sadasivam, B., & Joshi, R. P. (2020) · Diabetology International · doi:10.1007/s13340-020-00472-4 · Cited by 25
Lu, J., Fu, L., Li, Y., Geng, J., Qin, L., Li, P., Zheng, H., Sun, Z., Li, Y., Zhang, L., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14314 · Cited by 27
The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction
Genuardi, M. V., & Mather, P. J. (2021) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/17539447211002678 · Cited by 27
Attimarad, M., Venugopala, K. N., Nair, A. B., Sreeharsha, N., & Deb, P. K. (2022) · Separations · doi:10.3390/separations9020023 · Cited by 29
Górriz, J. L., Romera, I., Cobo, A., O’Brien, P. D., & Merino-Torres, J. F. (2022) · Diabetes Therapy · doi:10.1007/s13300-021-01198-5 · Cited by 31
Peng, Y., Qin, D., Wang, Y., Xue, L., Qin, Y., & Xu, X. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2022.1081920 · Cited by 28
“Previous literature reports demonstrated that metformin has beneficial effects on glucose homeostasis control and CVD (Andersson et al., 2010; Elder et al., 2016).”
BackgroundDiaz-Thomas, A., Golden, S. H., Dabelea, D., Grimberg, A., Magge, S. N., Safer, J. D., Shumer, D. E., & Stanford, F. C. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad124 · Cited by 29
Trakoonsenathong, R., Kunprom, W., Aphivatanasiri, C., Yueangchantuek, P., Pimkeeree, P., Sorin, S., Khawkhiaw, K., Chiu, C., Okada, S., Wongkham, S., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-64774-2 · Cited by 26
A territory‐wide study on the impact of COVID‐19 on diabetes‐related acute care
Lui, D. T. W., Lee, C., Chow, W. S., Fong, C. H. Y., Woo, Y. C., Lam, K. S. L., & Tan, K. C. B. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13368 · Cited by 26
Targeting Myocardial Substrate Metabolism in the Failing Heart: Ready for Prime Time?
Yurista, S. R., Chen, S., Welsh, A., Tang, W. H. W., & Nguyen, C. T. (2022) · Current Heart Failure Reports · doi:10.1007/s11897-022-00554-1 · Cited by 29
Safety and effectiveness of metformin in patients with reduced renal function: a systematic review
Orloff, J., Min, J. Y., Mushlin, A., & Flory, J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14440 · Cited by 24
Horii, T., Masudo, C., Takayanagi, Y., Oikawa, Y., Shimada, A., & Mihara, K. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14265 · Cited by 28
“One factor hindering the proactive use of traditional GLP-1RAs is the need for subcutaneous administration, given that some patients prefer oral medications to injectables 5,6 , and a reported decline in treatment adherence with injections 6,7 .”
BackgroundSiddiqui, H. F., Waqas, S. A., Batool, R. M., Salim, H., Minhas, A. M. K., Hasni, S. F., Alsaid, A., Sannino, A., Afzal, A. M., & Khan, M. S. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10523-0 · Cited by 25
“For patients in whom SGLT2 inhibitors are contraindicated or poorly tolerated, GLP-1RAs remain a reasonable alternative, though careful selection and monitoring are essential [44, 45].”
Ji, L., Chan, J. C. N., Yu, M., Yoon, K., Kim, S. G., Choi, S. H., Huang, C., Tu, S., Wang, C., Paldánius, P. M., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14205 · Cited by 28
Giorgino, F., Caruso, I., & Napoli, R. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108478 · Cited by 24
Ertugliflozin in the treatment of type 2 diabetes mellitus
Marrs, J. C., & Anderson, S. L. (2020) · Drugs in Context · doi:10.7573/dic.2020-7-4 · Cited by 31
Bazmandegan, G., Zamanian, M. Y., Giménez‐Llort, L., Nikbakhtzadeh, M., Kamiab, Z., & Heidari, M. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220620143655 · Cited by 25
Vinci, M. C., Gambini, E., Bassetti, B., Genovese, S., & Pompilio, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113864 · Cited by 25
Luo, M.-H., Kong, X., Wang, H., Zhai, X., Cai, T., Ding, B., Hu, Y., Jing, T., Su, X., Li, H., et al. (2020) · Journal of Diabetes Research · doi:10.1155/2020/6666403 · Cited by 24
“atherosclerotic cardiovascular disease [24].”
Carrillo-Larco, R. M., Castillo‐Cara, M., Anza‐Ramirez, C., & Bernabé‐Ortiz, A. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001889 · Cited by 25
Abushanab, D., Al‐Badriyeh, D., Liew, D., & Ademi, Z. (2021) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2021.100852 · Cited by 25
Personal Health Knowledge Graph for Clinically Relevant Diet RecommendationsPreprint
Seneviratne, O. W., Harris, J. J., Chen, C.-H., & McGuinness, D. L. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2110.10131 · Cited by 24
Hypoglycemia communication in primary care visits for patients with diabetes
Pilla, S. J., Park, J., Schwartz, J. L., Albert, M. C., Ephraim, P. L., Boulware, L. E., Mathioudakis, N. N., Maruthur, N. M., Beach, M. C., & Greer, R. C. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-020-06385-x · Cited by 23
Fiorini, G., Cortinovis, I., Corrao, G., Franchi, M., Pincelli, A. I., Perotti, M., Rigamonti, A. E., Sartório, A., & Cella, S. G. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17218169 · Cited by 24
Recent advances in new-onset diabetes mellitus after kidney transplantation
Montada-Atin, T., & Prasad, G. V. R. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i5.541 · Cited by 24
Euh, W., Lim, S. K., & Kim, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.613389 · Cited by 25
Han, Y., Cheng, B., Guo, Y., Wang, Q., Yang, N., & Lin, P. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.779636 · Cited by 24
Emerging Nonpharmacologic Interventions to Treat Diabetic Peripheral Neuropathy
Enders, J. D., Elliott, D., & Wright, D. E. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0158 · Cited by 25
“For most type 2 diabetic patients, Metformin is commonly used with other approaches, including insulin (American Diabetes Association, 2020).”
Potential Global Impact of Sodium–Glucose Cotransporter-2 Inhibitors in Heart Failure
Talha, K. M., Butler, J., Greene, S. J., Aggarwal, R., Anker, S. D., Claggett, B. L., Docherty, K. F., Solomon, S. D., McMurray, J. J. V., Januzzi, J. L., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2864 · Cited by 24
Gao, L., Ran, X., Liu, X., Shen, X., Chen, S., Liu, F., Zhao, D., Bi, Y., Su, Q., Lu, Y., et al. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13428 · Cited by 23
Long-term exposure of human endothelial cells to metformin modulates miRNAs and isomiRs
Giuliani, A., Londin, E. R., Ferracin, M., Mensa’, E., Prattichizzo, F., Ramini, D., Marcheselli, F., Recchioni, R., Rippo, M. R., Bonafè, M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-78871-5 · Cited by 23
Antiobesity drug therapy: An individualized and comprehensive approach
Mauer, Y., Parker, M., & Kashyap, S. R. (2021) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.20080 · Cited by 26
Rayner, C. K., Wu, T., Aroda, V. R., Whittington, C., Kanters, S., Guyot, P., Shaunik, A., & Horowitz, M. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14202 · Cited by 23
Qian, B.-B., Chen, Q., Li, L., & Yan, C.-F. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05590-y · Cited by 22
Dimosthenopoulos, C., Liatis, S., Kourpas, E., Athanasopoulou, E., Driva, S., Makrilakis, K., & Kokkinos, A. D. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14390 · Cited by 22
Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines
Mehta, R., Chen, R., Hirose, T., John, M., Kok, A., Lehmann, R., Unnikrishnan, A., Yavuz, D. G., & Fulcher, G. R. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14128 · Cited by 27
Adherencia a un estilo de vida saludable en pacientes con diabetes mellitus tipo 2 en España
Unanua, M. P. P., Fernández, M. A., Simarro, F. L., Llora, T. S., Martínez, I. P., & Romero, J. M. (2020) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2020.08.009 · Cited by 22
“El abordaje terapéutico de esta enfermedad es multi-disciplinar e incluye tanto estrategias farmacológicas como no farmacológicas 3 esenciales en la persona con diabetes 4 5,6 de conducta inadecuados.”
Cheung, Y.-M. M., McDonnell, M., & Hamnvik, O.-P. R. (2022) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100776 · Cited by 21
Robinson, S. J., Boye, K. S., Mody, R., Strizek, A., Кониг, М., Malik, R., & Kennedy‐Martin, T. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00839-5 · Cited by 25
Pharmacokinetics and Clinical Implications of Oral Semaglutide for Type 2 Diabetes Mellitus
Clements, J. N., Isaacs, D. M., Hartman, R. E., & Gambill, K. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00951-6 · Cited by 22
Rikin, S., Deccy, S., Zhang, C., Crandall, J. P., Deng, Y., & Golestaneh, L. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-022-07863-0 · Cited by 22
Attaye, I., Lassen, P. B., Adriouch, S., Steinbach, E., Patiño‐Navarrete, R., Davids, M., Alili, R., Jacques, F., Benzeguir, S., Belda, E., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107471 · Cited by 21
Al-Hindi, B., Mohammed, M. A., Mangantig, E., & Martini, N. D. (2023) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2023.10.010 · Cited by 21
Effect of metformin on outcome after acute ischemic stroke in patients with type 2 diabetes mellitus
Kersten, C. J. B. A., Knottnerus, I. L. H., Heijmans, E., Haalboom, M., Zandbergen, A. A. M., & den Hertog, H. M. (2022) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2022.106648 · Cited by 21
Leung, V., Wroblewski, K., Schumm, L. P., Huisingh-Scheetz, M., & Huang, E. S. (2021) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glab141 · Cited by 21
Mohamed, S. (2024) · Medicine · doi:10.1097/md.0000000000040221 · Cited by 23
“[5] 1”
Cowart, K., Updike, W. H., Emechebe, N. C., & Zgibor, J. C. (2020) · Preventing Chronic Disease · doi:10.5888/pcd17.190377 · Cited by 20
Kiuchi, M. G., Ganesan, K., Keating, J. H., Carnagarin, R., Matthews, V. B., Herat, L. Y., Goh, G. S., Adams, L. A., & Schlaich, M. P. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-021-01814-1 · Cited by 20
SGLT2 Inhibitors, What the Emergency Physician Needs to Know: A Narrative Review
Lu, H. Y., Lu, H., Kosinski, C., Wojtusciszyn, A., Zanchi, A., Carron, P., Müller, M., Meyer, P., Martin, J., Müller, O., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10092036 · Cited by 21
Buzea, A., Manu, P., Dima, L., & Correll, C. U. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2147425 · Cited by 20
Empagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes
Tesfaye, H., Paik, J. M., Roh, M., Htoo, P. T., Zakoul, H., Schmedt, N., Koeneman, L., Wexler, D. J., & Patorno, E. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.5219 · Cited by 22
Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
Lo, C. W. H., Fei, Y., & Cheung, B. M. Y. (2021) · Cardiac failure review · doi:10.15420/cfr.2020.19 · Cited by 22
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-12-16
- Volume
- 43
- Issue
- Supplement_1
- Pages
- S98-S110
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4246340431
- Cited by
- 914
- References
- 84
- Citations by year
- 2026: 17 · 2025: 39 · 2024: 69 · 2023: 100 · 2022: 151 · 2021: 270 · 2020: 268
- FWCI
- 140.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Glycemic Control, Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Hypoglycemic Agents, Reference Standards, Societies, Medical, United States, History, 21st Century, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.